Introduction: Daratumumab is a human IgGκ monoclonal antibody targeting CD38 with a
direct on-tumor and immunomodulatory mechanism of action. Daratumumab induces rapid …

In POLLUX, daratumumab (D) plus lenalidomide/dexamethasone (Rd) reduced the risk of
disease progression or death by 63% and increased the overall response rate (ORR) versus …

Introduction: Daratumumab, a human IgGκ monoclonal antibody targeting CD38 with a
direct on-tumor and immunomodulatory mechanism of action, is approved in combination …

8025 Background: Daratumumab (D) is a human CD38-targeting mAb that significantly
prolongs progression-free survival (PFS) when added to standard-of-care regimens in …

PURPOSE With the initial analysis of POLLUX at a median follow-up of 13.5 months,
daratumumab in combination with lenalidomide and dexamethasone (D-Rd) significantly …

Introduction: Daratumumab is a human monoclonal antibody targeting CD38 that
demonstrated superior efficacy in combination with lenalidomide and dexamethasone (DRd) …

Introduction: Daratumumab is a human, CD38-targeted, IgGκ monoclonal antibody with both
direct on-tumor and immunomodulatory mechanisms of action. In the phase 3 POLLUX …

Introduction: Daratumumab (DARA) is a human IgGκ monoclonal antibody targeting CD38
with a direct on-tumor and immunomodulatory mechanism of action. DARA is approved as …

Introduction: Daratumumab is an anti-CD38 IgGκ monoclonal antibody that has been
combined successfully with lenalidomide and dexamethasone. The combination of …

Introduction: Daratumumab (D) is a human monoclonal antibody targeting CD38 that is
approved as a monotherapy and in combination with standard of care regimens for patients …